The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:
Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D. Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their biomarker product or technology as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study. Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis. Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this study. In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.
The overall biomarkers sector is comprised of a variety of fast-growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Each sub-section contains detailed forecasts for each driving mechanism, or relevant area of growth.
Information to prepare this report was obtained from participating and emerging comp
|SOURCE MDX |
Copyright©2010 PR Newswire.
All rights reserved